A few words on Tesla as The Ultimate Story Stock.
I don’t think this board really wants a full analysis of TSLA, which is why I didn’t mention the company by name. If anyone thinks we do, a new thread should be started. I’d be happy to participate.
For this thread, to keep it somewhat aligned with the original subject, I’ll just point out that a major difference between the NKTR story and the TSLA story is that Tesla is far more in control of its own success. NKTR has to wait to see how the tests/studies go and then how they’re interpreted. Tesla just needs to build cars more quickly.
And, I believe one can make a decent assessment of whether Tesla has the engineering chops to speed up production quickly enough, and whether Tesla management (Elon and Deepack Ahuja) has the financial insight and levers in place to keep the company going and growing until then. I don’t know the biomedical world, but what I’ve seen is that there’s strong disagreement on whether Nektar’s drug is in fact even successful or not. And if it proves to be not as successful as the FDA (?) wants, with as small known side-effects as the FDA wants, I don’t believe Nektar has any levers in place to change that and try again, whereas Tesla can tweak their assembly line continuously as long as they have enough money for operations.
Finally, we can run the numbers on Tesla’s revenue, cash flow, costs of operations, etc. We can then factor in expected production rates to see what the company’s financial condition would be under various circumstances, and then choose to rate the likelihood of those circumstances occurring to make our investment decisions. With Nektar, it’s all a bet on whether something already designed and unchangeable will do what they hope it will do. That makes Nektar far more speculative than Tesla (that’s not to say that Tesla is less risky, just that one has to speculate as to the risk in Nektar whereas one can determine the risk within certain boundaries with Tesla).
Tesla was the Ultimate Story stock back before 2014. Back then, no-one knew whether they could engineer an entirely new car on their own (Roadster was a Lotus-produced glider with a Tesla drivetrain), much less knew what the real demand was, much less what the gross margins on the vehicle would be. Today we have much more information and so one doesn’t need to rely on a story to make an investment decision. That’s not yet true with Nektar.